SEARCH

SEARCH BY CITATION

References

  • 1
    UNAIDS. UNAIDS Data Tables 2011. Available at www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2225_UNAIDS_datatables_en.pdf (accessed 1 February 2012).
  • 2
    Murray C, Rosenfeld L, Lim S et al. Global malaria mortality between 1980 and 2010: a systematic review. Lancet 2012; 379: 413431.
  • 3
    World Health Organization guidelines for the treatment of malaria, 2nd edn. Available at www.who.int/malaria/publications/atoz/9789241547925/en/index.html (accessed 18 April 2012).
  • 4
    Byakika-Kibikwa P, Lamorde M, Mayanja-Kizza H, Khoo S, Merry C, Van Geertruyden JP. Artemether-lumefantrine combination therapy for treatment of uncomplicated malaria: the potential for complex interactions with antiretroviral drugs in HIV-infected individuals. Malaria Research and Treatment 2011, Article ID 703730 (5 pages).
  • 5
    Bassat Q. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl Trop Dis 2011; 5: e1325.
  • 6
    Novartis Ltd. Riamet 20/120mg tablets. Summary of Product Characteristics. Available at www.medicines.org.uk/emc/medicine/9196/SPC/ (accessed 28 September 2012).
  • 7
    Byakika-Kibwika P, Lamorde M, Mayanja-Kizza H, Merry C, Colebunders R, Van Geertruyden JP. Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria. Ther Clin Risk Manag 2009; 5: 110.
  • 8
    European AIDS Clinical Society (EACS). Guidelines for the clinical management of HIV infected adults in Europe. October 2011. Available at www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41 (accessed 17 October 2011).
  • 9
    The Department for Health and Human Services (DHHS). DHHS guidelinesPanel on Antiretroviral Guidelines for Adults and Adolescents. Guidelnes for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. March 2012. Available at http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/37/whats-new-in-the-guidelines- (accessed 5 April 2012).
  • 10
    Medecins Sans Frontieres Access Campaign. Medecins Sans Frontieres Access Campaign: untangling the web of antiretroviral price reductions. 14th edn. July 2011. Available at http://utw.msfaccess.org/ (accessed 1 February 2012).
  • 11
    Djimimde A, Levevre G. Understanding the pharmacokinetics of Coartem. Malar J 2009; 8 (Suppl 1): S4.
  • 12
    Kredo T, Mauff K, Van der Walt JS et al. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother 2011; 55: 56165623.
  • 13
    Byakika-Kibwika P, Lamorde M, Mayito J et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67: 22132221.
  • 14
    Soyinka J, Onyeji C, Omoruyi S, Owolabi A, Sarma P, Cook J. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol 2009; 61: 439443.
  • 15
    Huang L, Parikh S, Rosenthal PJ et al. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr 2012; 61: 310316.
  • 16
    German P, Parikh S, Lawrence J et al. Lopinavir/ritonavir affects pharmacokinetic exposure of arthemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009; 51: 424429.
  • 17
    Byakika-Kibwika P, Lamorde M, Okaba-Kayom V et al. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67: 12171223.
  • 18
    Kredo T, Van der Walt J, Mauff K et al. The interaction between artemether-lumefantrine and ritonavir boosted lopinavir-based antiretroviral therapy in HIV infected people. 19th Conference on Retroviruses and opportunistic infections. Seattle, UK, March 2012 [Abstract 613].
  • 19
    Byakika-Kibwika P, Lamorde M, Lwabi P et al. Cardiac conduction safety during coadministration of artemether-lumefantrine and lopinavir/ritonavir in HIV-infected Ugandan adults. Chemother Res Pract. 2011; 2011: 393976.
  • 20
    Katlama C, Haubrich R, Lalezari J et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 22892300.
  • 21
    Kakuda T, Wade J, Snoeck E et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced patients. Clin Pharmacol Ther 2010; 88: 695703.
  • 22
    Madruga J, Berger D, McMurchie M et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized, controlled Phase III trial. Lancet 2007; 370: 4958.
  • 23
    Katlama C, Esposito R, Gatell JM et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395402.
  • 24
    Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21: F11F18.
  • 25
    Cahn P, Fourie J, Grinzstein B et al. Week 48 analysis of once-daily versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1 infected patients. AIDS 2011; 25: 929939.
  • 26
    Schöller-Gyüre M, Kakuda TN, Sekar V et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12: 789796.
  • 27
    Fridericia L. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkanken. Acta Med Scand 1920; 53: 469486.
  • 28
    Ortiz R, DeJesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir-ritonavir in treatment naïve HIV-1 infected patients at Week 48. AIDS 2008; 22: 13891397.
  • 29
    Nsanzabana C, Rosenthal P. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob Agents Chemother 2011; 55: 50735077.
  • 30
    Martin R, Butterworth A, Gardiner D, Kirk K, McCarthy J, Skinner-Adams T. Saquinavir inhibits the malaria parasite's chloroquine resistance transporter. Antimicrob Agents Chemother 2012; 56: 22832289.
  • 31
    Achan J, Kahuru A, Iklezi G, Ruel T, Clark T. Charlebois et al. Significant reduction in risk of malaria among HIV+ children receiving lopinavir/ritonavir based ART compared to NNRTI based ART – a randomised, open-label trial. 19th Conference on Retroviruses and opportunistic infections. Seattle, UK, March 2012 [Abstract 26].